Latest Global Expansion News

Servcorp Limited reported a landmark FY25 with revenue up 11% to $352.1 million and net profit after tax rising 36% to $53.1 million, driven by disciplined execution and strategic global expansion.

Tetratherix has landed a $3.3 million Australian Government grant to co-fund a $7.4 million project expanding its synthetic polymer production and supporting its US market entry in 2026.

Iondrive Limited has won a $3.9 million government grant to advance its innovative urban mining technology, accelerating the construction of a pilot plant focused on critical minerals recovery from lithium-ion batteries.

Audeara Limited has secured a five-year licensing agreement with Eastech (Huizhou) Co., Ltd. to bring its advanced hearing technology to China’s booming medical device market, leveraging major e-commerce platforms for distribution.

RooLife Group Ltd has successfully raised $2 million through an oversubscribed strategic placement, positioning the company to expand its e-commerce footprint across key international markets.

X2M Connect Limited has completed a $309,000 entitlement offer by issuing 23.76 million new shares and options, while a substantial shortfall of nearly 127 million shares remains available for placement.

Pinnacle Investment Management Group delivered a robust FY2025 with a 49% rise in net profit and a 63% jump in funds under management, driven by strategic international growth and strong affiliate performance.

HeraMED advances AI-driven maternity care partnerships and strengthens its US commercial team, navigating policy uncertainties while progressing its global expansion and funding strategies.

Advanced Health Intelligence Ltd has secured up to AUD 5.5 million from Oakley Capital Partners to support its ASX reinstatement and global expansion, while targeting an additional USD 6 million and unlocking $3 million in R&D grants.

Advanced Health Intelligence Ltd has locked in up to AUD 5.5 million from Oakley Capital Partners, reinforcing its capital base as it pushes toward reinstatement on the ASX and broader growth ambitions.

Tissue Repair Limited reports steady progress in its Phase 3 clinical trials for TR987® despite patient recruitment hurdles, while TR Pro+® sales surge and new distribution deals pave the way for international growth.

Eden Innovations reports a striking 114% year-on-year jump in Q4 US sales of its EdenCrete® products, alongside a 50% annual sales increase and significant debt reduction plans.